Area of Interest: North America
What we are looking for:
One focus of our company relevant to North America is to work with further licensing partners for our innovative abuse deterrent formulation technology, INTAC®. We are interested in collaborating to produce extended and / or immediate release INTAC® technology on a commercial scale.
For more information, please see http://www.intac.grunenthal.com
Read our recent press releases on Grünenthal partnering projects in North America and on INTAC
-
Grünenthal has acquired US-based Thar Pharmaceuticals Inc. to expand its development portfolio of treatment options for CRPS (Complex Regional Pain Syndrome), a serious, disabling orphan disease
-
Patheon selected by Grünenthal to develop drugs using Intac® abuse deterrent formulations technology
-
Grünenthal GmbH exclusively licenses U.S. and Canadian rights of its innovative analgesic Cebranopadol to Depomed, Inc., confirming their strategic partnership
-
Grünenthal GmbH granted its consent to the transfer of the license rights for Nucynta® (tapentadol) in the U.S. from Janssen Pharmaceuticals, Inc., to Depomed, Inc.
-
FDA approval of reformulated scheduled analgesic product using Grünenthal's INTAC™ technology
